Sionna expands its pipeline of CFTR modulators with AbbVie’s assets
Sionna Therapeutics has gained the rights to develop and market three of AbbVie’s clinical-stage compounds, a move that expands the company’s pipeline of small molecules that are designed to restore the function of the CFTR protein, which is faulty or absent in cystic fibrosis (CF). The compounds…